vafidemstat

inhibitor of KDM1A and MAOB

Also Known As:

(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; ORY-2001

Networked: 5 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Oxazoles: 89
      - Oxadiazoles: 146
        vafidemstat: 5

Experts

1.	Maes, Tamara: 2 articles (01/2021 - 01/2020)
2.	Mascaró, Cristina: 2 articles (01/2021 - 01/2020)
3.	Antonijoan, Rosa María: 1 article (01/2021)
4.	Arévalo, María Isabel: 1 article (01/2021)
5.	Buesa, Carlos: 1 article (01/2021)
6.	Coimbra, Jimena: 1 article (01/2021)
7.	Ferrero-Cafiero, Juan Manuel: 1 article (01/2021)
8.	Martínez-Colomer, Joan: 1 article (01/2021)
9.	Molinero, Cesar: 1 article (01/2021)
10.	Puntes, Montse: 1 article (01/2021)

Related Diseases

1.	Multiple Sclerosis 07/06/2022 - "Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis." 07/06/2022 - "Here, we investigated the effect of ORY-2001 on immune-mediated and virus-induced encephalomyelitis, two experimental models of multiple sclerosis and neuronal damage. "
2.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 07/06/2022 - "Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis."
3.	Neurodegenerative Diseases (Neurodegenerative Disease) 07/06/2022 - "These results pointed to ORY-2001 as a promising CNS epigenetic drug able to target neuroinflammatory and neurodegenerative diseases and provided preclinical support for the subsequent design of early-stage clinical trials."
4.	Central Nervous System Diseases (CNS Diseases) 01/01/2021 - "The study aimed to determine the safety and tolerability of vafidemstat, to characterize its pharmacokinetic and pharmacodynamic profiles, to assess its central nervous system (CNS) exposure, and to acquire the necessary data to select the appropriate doses for long-term treatment of patients with CNS disease in phase II trials. "
5.	Alzheimer Disease (Alzheimer's Disease) 01/01/2020 - "Multiple genes modulated by ORY-2001 are differentially expressed in Late Onset Alzheimer's Disease. " 01/01/2020 - "ORY-2001 efficiently inhibits brain KDM1A at doses suitable for long term treatment, and corrects memory deficit as assessed in the novel object recognition testing in the Senescence Accelerated Mouse Prone 8 (SAMP8) model for accelerated aging and Alzheimer's disease. " 01/01/2023 - "Another TCP-based LSD1/MAO-B dual inhibitor, vafidemstat (ORY-2001), is in clinical trial for Alzheimer's diseases and personality disorders. "

Related Drugs and Biologics

1.	Monoamine Oxidase (MAO)
2.	pulrodemstat besilate

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration